. 2004 Jul 27;91(4):678–682. doi: 10.1038/sj.bjc.6602042

Table 2. UGT1A1^*28 genotypes and bilirubin levels (μmol l⁻¹) prior to irinotecan administration and the highest value during therapy.

Genotypea	N	Bilirubin premean (range)	Bilirubin higher mean (range)	P*
6/6	40	8.3 (4–22)	9.9 (4–25)	0.001
6/7	45	8.7 (4–18)	13 (5–37)	0.001
7/7	10	15 (6–28)	22 (6–65)	0.1
P	—	0.001	0.001

Symbols of (6/6), (6/7) and (7/7) denote homozygous absence of the variant allele, heterozygous, and homozygous for the variant allele, respectively. P=Significance of comparisons of bilirubin levels between genotypes. P^*=Significance of comparisons of bilirubin levels pre- and postchemotherapy.

Table 2. UGT1A1*28 genotypes and bilirubin levels (μmol l−1) prior to irinotecan administration and the highest value during therapy.

Table 2. UGT1A1^*28 genotypes and bilirubin levels (μmol l⁻¹) prior to irinotecan administration and the highest value during therapy.